CN101502458A - Therapeutic corneal contact lens - Google Patents
Therapeutic corneal contact lens Download PDFInfo
- Publication number
- CN101502458A CN101502458A CNA2009100964449A CN200910096444A CN101502458A CN 101502458 A CN101502458 A CN 101502458A CN A2009100964449 A CNA2009100964449 A CN A2009100964449A CN 200910096444 A CN200910096444 A CN 200910096444A CN 101502458 A CN101502458 A CN 101502458A
- Authority
- CN
- China
- Prior art keywords
- contact lens
- corneal contact
- therapeutic
- modified
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to medical appliances of ocular surface and cornea diseases, in particular to a therapeutic corneal contact lens. The therapeutic corneal contact lens is characterized in that the therapeutic corneal contact lens is a sphere-shaped component made of methacrylic acid-2-hydroxyethyl ester monomer or copolymer or hydrogels; the internal surface of the corneal contact lens is modified with medicines. The therapeutic corneal contact lens has sufficient mechanical strength, can provide effective mechanical protection, can boost healing of corneal epithelium and stroma and has longer degradation time than the lens made of collagen solely. The therapeutic corneal contact lens with different functions can be produced by modifying different medicines such as antibiotics, growth factors, and immunosuppressants, vascular endothelial cell growth inhibitors and the like on the internal surface.
Description
Technical field
The present invention relates to eye table and keratopathy medical apparatus and instruments, be specifically related to a kind of therapeutic corneal contact lens.
Background information
Eye table operation back is as PRK, LASIK postoperative, corneal epithelium can lack or be impaired, the healing fully of general post-operative cornea epithelium needs 3 to 7 days, during this period, the stimulation of any machinery such as the closing motion of eyelid all can cause coming off again of corneal epithelium, therefore need a kind of eyeglass of approximate corneal contact lens to cover at the eye table, make anterior corneal surface avoid the mechanical stimulus that the catacleisis motion brings, thereby, promote the growth of corneal epithelium for corneal epithelium provides stable growing environment.Can reduce simultaneously because of corneal epithelium disappearance or damaged eye irritation and the pain that causes.In other cases; under situations such as cornea wound, chemical injury, corneal infection disease, noninfectious disease such as cornea epithelial erosion, need a kind of medical apparatus and instruments that mechanical protection, simultaneously but also can promote epithelial growth and corneal stroma healing not only can corneal be provided equally.Amnion transplantation has similar therapeutical effect clinically.Amniotic membrane is the tissue of embryonic origin, after strict handling process, amnion tissue can be applied in above-mentioned eye surface diseases, because of containing the multiple nutrients factor such as epidermis epithelium growth factor etc. in the amniotic membrane, a table transplanting has the healing of the epithelium of promotion, minimizing new vessels, effects such as reaction and minimizing cicatrization reduce inflammation.But amniotic membrane can not carry the target medicine, and amnion transplantation is operative treatment, all complication that exist operation to be caused, and the amniotic membrane dissolving after transplanting simultaneously is fast, often needs the repeat surgery treatment.And have the binder formula contact lens of approximate effect only can play the mechanical protection effect; do not promote corneal epithelium and substrate healing effect; binder formula contact lens is because the restriction of material in addition; also still can not carry the target medicine at different eye surface diseases and treat, therefore limit Clinical Application.
Summary of the invention
The objective of the invention is to provides a kind of have sufficient mechanical strength, portability target medicine, the slower therapeutic corneal contact lens of degradation speed for overcoming the deficiencies in the prior art.
For achieving the above object, the invention discloses a kind of therapeutic corneal contact lens and preparation method thereof, therapeutic corneal contact lens adopts macromolecular material to make sphere shape member, and its inner surface is modified with medicine.These macromolecular materials can be methacrylic acid-2-hydroxy methacrylate (HEMA) monomer, methacrylic acid-2-hydroxy methacrylate (HEMA) monomer copolymer, hydrogel material or collagen-chitosan mixed film.
The therapeutic corneal contact lens manufacture method may further comprise the steps:
(1) methacrylic acid-2-hydroxy methacrylate (HEMA) monomer or its copolymer or hydrogel are dissolved in the acid solution of 1%-5%;
(2) it is dry above-mentioned solution to be injected mould;
(3) add in the mould after 2%～5% aqueous slkali soaking 20-40 minute and take off film;
(4) oven dry said products and make it reach the suction balance;
(5) prepared film being made into diameter by rotational forming, turning molding, the method for mixing autofrettage or moldings formed therefrom is 13mm～15mm, and basic arc is the sphere shape corneal contact lens of 6.0mm-9.0mm;
(6) corneal contact lens inner surface is modified, and the load different pharmaceutical is as antibiotic, somatomedin, immunosuppressant, blood vessel endothelium inhibitive factor etc.
Therapeutic corneal contact lens adopts macromolecular materials such as methacrylic acid-2-hydroxy methacrylate (HEMA) monomer, methacrylic acid-2-hydroxy methacrylate (HEMA) monomer copolymer, hydrogel material or collagen-chitosan mixed film to make, shape and eyeball surface match, therefore have enough mechanical strengths, can provide effective mechanical protection for the eye table, can promote the healing of corneal epithelium and substrate, and with by separately having longer degradation time with comparing of making of collagen; Can also stay the time by the storage that prolongs the medication of eye table, improve the bioavailability of eye drop, by different pharmaceuticals such as internal finishing such as antibiotic, somatomedin, immunosuppressant, blood vessel endothelium inhibitive factor, can make the therapeutic corneal contact lens of difference in functionality.
The specific embodiment
This therapeutic corneal contact lens is made sphere shape member for adopting macromolecular material, and its inner surface is modified with medicine.
Therapeutic corneal contact lens is by a kind of sphere shape member of making in methacrylic acid-2-hydroxy methacrylate (HEMA) monomer or its copolymer or the hydrogel material, the shape of therapeutic corneal contact lens will match with eyeball surface, usually making diameter is 13mm～15mm, the base arc is the sphere shape of 6.0mm-9.0mm, according to the treatment needs, be modified with in antibiotic, somatomedin, immunosuppressant, the blood vessel endothelium inhibitive factor one or more at the therapeutic corneal contact lens inner surface.Specific embodiment is as follows:
Specific embodiment 1:
The therapeutic corneal contact lens manufacture method may further comprise the steps:
(1) methacrylic acid-2-hydroxy methacrylate (HEMA) monomer is dissolved in 1% acetic acid solution
(2) it is dry above-mentioned solution to be injected mould;
(3) ammonia spirit of adding 2% in the mould soaks and takes off film after 20 minutes;
(4) oven dry said products and make it reach the suction balance;
(5) prepared film being made into diameter by rotational forming, turning molding, the method for mixing autofrettage or moldings formed therefrom is 13mm～15mm, and basic arc is the sphere shape corneal contact lens of 6.0mm-9.0mm;
(6) corneal contact lens inner surface is modified, and makes immunosuppressant in its load, blood vessel endothelium inhibitive factor.
The therapeutic corneal contact lens manufacture method can also be following steps:
(1) methacrylic acid-2-hydroxy methacrylate (HEMA) monomer copolymer is dissolved in 3% hydrochloric acid solution;
(2) it is dry above-mentioned solution to be injected mould;
(3) sodium hydroxide solution of adding 25% in the mould soaks and takes off film after 30 minutes;
(4) oven dry said products and make it reach the suction balance;
(5) prepared film being made into diameter by the rotational forming method is 13mm～15mm, and basic arc is the sphere shape corneal contact lens of 6.0mm-9.0mm;
(6) corneal contact lens inner surface is modified, and makes antibiotic, somatomedin etc. in its load.
The therapeutic corneal contact lens manufacture method can also be following steps:
(1) hydrogel is dissolved in 3% hydrochloric acid solution;
(2) it is dry above-mentioned solution to be injected mould;
(3) sodium hydroxide solution of adding 3% in the mould soaks and takes off film after 40 minutes;
(4) oven dry said products and make it reach the suction balance;
(5) prepared film being made into diameter by the turning forming method is 13mm～15mm, and basic arc is about the sphere shape corneal contact lens of 50 μ m for the 6.0mm-9.0mm thickness;
(6) corneal contact lens inner surface is modified, and makes antibiotic in its load.
Specific embodiment 2:
Therapeutic corneal contact lens is made sphere shape member by collagen-chitosan mixed film, and wherein the collagen mass content is 1%-95%, and is good with the collagen mass content 15%, and described chitosan and collagen are crosslinked by cross-linking agent.The shape of therapeutic corneal contact lens will match with eyeball surface, usually making diameter is 13mm～15mm, the base arc is the sphere shape of 6.0mm-9.0mm, according to the treatment needs, be modified with in antibiotic, somatomedin, immunosuppressant, the blood vessel endothelium inhibitive factor one or more at the therapeutic corneal contact lens inner surface.The therapeutic corneal contact lens manufacture method may further comprise the steps:
(1) chitosan, collagen are dissolved in respectively in the acid solution (as acetic acid, hydrochloric acid etc.) in proportion;
(2) acid solution with chitosan and collagen mixes, and stirs under the room temperature 1～2 hour, and removes bubble in supersonic oscillations 5-30 minute, make the abundant mix homogeneously of each component, usually stir more than 1 hour, supersonic oscillations were removed bubble in 10 minutes, can reach abundant mix homogeneously;
(3) in above-mentioned mixed liquor, add with 0.1%～0.25% water miscible carbodiimide as the cross-linking agent crosslinking Treatment;
(4) solution after crosslinked injects the mould natural drying with cross-linking agent;
(5) adding 2%～5% aqueous slkali (as sodium hydroxide solution or ammonia etc.) in the mould soaks after 20-40 minute and takes off film;
(6) oven dry said products and make it reach the suction balance;
(7) prepared film being made diameter by rotational forming, turning molding, the method for mixing autofrettage method or moldings formed therefrom is 13mm～15mm, and basic arc is 6.0mm-9.0mm, and thickness is about the sphere shape corneal contact lens of 50 μ m;
(8) corneal contact lens inner surface is modified, and makes antibiotic, somatomedin, immunosuppressant and blood vessel endothelium inhibitive factor in its load simultaneously.
Claims (7)
1, a kind of therapeutic corneal contact lens is characterized in that: the sphere shape member of described corneal contact lens for being made by methacrylic acid-2-hydroxy methacrylate monomer or its copolymer or hydrogel material, its inner surface is modified with medicine.
2, therapeutic corneal contact lens according to claim 1 is characterized in that: described therapeutic corneal contact lens inner surface is modified with one or more in antibiotic, somatomedin, immunosuppressant, the blood vessel endothelium inhibitive factor.
3, the described therapeutic corneal contact lens manufacture method of a kind of claim 1 is characterized in that may further comprise the steps:
(1) methacrylic acid-2-hydroxy methacrylate monomer or its copolymer or hydrogel are dissolved in the acid solution of 1%-5%;
(2) it is dry above-mentioned solution to be injected mould;
(3) add in the mould after 2%～5% aqueous slkali soaking 20-40 minute and take off film;
(4) oven dry said products and make it reach the suction balance;
(5) prepared film being made into diameter by rotational forming, turning molding, mixing autofrettage or moldings formed therefrom method is 13mm～15mm, and basic arc is the sphere shape corneal contact lens of 6.0mm-9.0mm;
(6) corneal contact lens inner surface is modified, and the load different pharmaceutical is as antibiotic, somatomedin, immunosuppressant, blood vessel endothelium inhibitive factor.
4, a kind of therapeutic corneal contact lens, it is characterized in that: the sphere shape member of described therapeutic corneal contact lens for making by collagen-chitosan mixed film, wherein the collagen mass content is 1%-95%, described chitosan and collagen are crosslinked by cross-linking agent, and described therapeutic corneal contact lens inner surface is modified with medicine.
5, therapeutic corneal contact lens according to claim 4 is characterized in that: described therapeutic corneal contact lens inner surface is modified with one or more in antibiotic, somatomedin, immunosuppressant, the blood vessel endothelium inhibitive factor.
6, according to claim 4 or 5 described therapeutic corneal contact lens, it is characterized in that: described wherein collagen mass content is 15%.
7, the described therapeutic corneal contact lens manufacture method of a kind of claim 4 is characterized in that may further comprise the steps:
(1) chitosan, collagen are dissolved in acid solution respectively by proportion of composing;
(2) acid solution with chitosan and collagen mixes, and stirs under the room temperature 1～2 hour, and removes bubble in supersonic oscillations 5-30 minute, makes the abundant mix homogeneously of each component;
(3) in above-mentioned mixed liquor, add the cross-linking agent crosslinking Treatment;
(4) with cross-linking agent the solution after crosslinked to inject mould dry;
(5) add 2%～5% aqueous slkali in the mould, soak and take off film after 20-40 minute;
(6) oven dry said products and make it reach the suction balance;
(7) prepared film being made into diameter by rotational forming, turning molding, the method for mixing autofrettage or moldings formed therefrom is 13mm～15mm, and basic arc is the sphere shape corneal contact lens of 6.0mm-9.0mm;
(8) corneal contact lens inner surface is modified, and the load different pharmaceutical is as antibiotic, somatomedin, immunosuppressant, blood vessel endothelium inhibitive factor etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100964449A CN101502458A (en) | 2009-03-03 | 2009-03-03 | Therapeutic corneal contact lens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100964449A CN101502458A (en) | 2009-03-03 | 2009-03-03 | Therapeutic corneal contact lens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101502458A true CN101502458A (en) | 2009-08-12 |
Family
ID=40974925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2009100964449A Pending CN101502458A (en) | 2009-03-03 | 2009-03-03 | Therapeutic corneal contact lens |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101502458A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102599991A (en) * | 2012-03-20 | 2012-07-25 | 中山大学中山眼科中心 | Application of beautifying cornea lens |
| CN102631711A (en) * | 2012-05-16 | 2012-08-15 | 金陵科技学院 | Hydrogel corneal contact lenses drug carrier |
| CN104737063A (en) * | 2012-10-30 | 2015-06-24 | 金善镐 | Therapeutic contact lens |
| CN106109447A (en) * | 2016-07-28 | 2016-11-16 | 温州眼视光发展有限公司 | A kind of preparation method and applications of growth factor-loaded sodium alginate/composite membrane of polyvinyl alcohol with levofloxacin |
| CN109265592A (en) * | 2018-09-07 | 2019-01-25 | 清华大学深圳研究生院 | Contact lens and preparation method thereof with high antioxidant |
| CN109847109A (en) * | 2018-09-11 | 2019-06-07 | 滕宇池 | A kind of contact lens carrying medicine |
| CN110123520A (en) * | 2019-05-21 | 2019-08-16 | 广东普洛宇飞生物科技有限公司 | A kind of amnion stealth contact lense, preparation method and application |
| US10857028B2 (en) | 2016-09-30 | 2020-12-08 | Sara Heikali | Method and device for treating and managing diseased ocular tissue |
| CN112415773A (en) * | 2020-12-03 | 2021-02-26 | 山东省眼科研究所 | Medicine-carrying contact lens for promoting corneal epithelium injury repair and preparation method thereof |
-
2009
- 2009-03-03 CN CNA2009100964449A patent/CN101502458A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102599991A (en) * | 2012-03-20 | 2012-07-25 | 中山大学中山眼科中心 | Application of beautifying cornea lens |
| CN102631711A (en) * | 2012-05-16 | 2012-08-15 | 金陵科技学院 | Hydrogel corneal contact lenses drug carrier |
| CN102631711B (en) * | 2012-05-16 | 2014-03-26 | 金陵科技学院 | Hydrogel corneal contact lenses drug carrier |
| CN104737063A (en) * | 2012-10-30 | 2015-06-24 | 金善镐 | Therapeutic contact lens |
| CN106109447A (en) * | 2016-07-28 | 2016-11-16 | 温州眼视光发展有限公司 | A kind of preparation method and applications of growth factor-loaded sodium alginate/composite membrane of polyvinyl alcohol with levofloxacin |
| US10857028B2 (en) | 2016-09-30 | 2020-12-08 | Sara Heikali | Method and device for treating and managing diseased ocular tissue |
| US11419760B2 (en) | 2016-09-30 | 2022-08-23 | Sara Heikali | Method and device for treating and managing diseased ocular tissue |
| CN109265592B (en) * | 2018-09-07 | 2020-08-07 | 清华大学深圳研究生院 | Corneal contact lens with high oxidation resistance and preparation method thereof |
| CN109265592A (en) * | 2018-09-07 | 2019-01-25 | 清华大学深圳研究生院 | Contact lens and preparation method thereof with high antioxidant |
| CN109847109A (en) * | 2018-09-11 | 2019-06-07 | 滕宇池 | A kind of contact lens carrying medicine |
| CN110123520A (en) * | 2019-05-21 | 2019-08-16 | 广东普洛宇飞生物科技有限公司 | A kind of amnion stealth contact lense, preparation method and application |
| CN110123520B (en) * | 2019-05-21 | 2024-03-26 | 广东普洛宇飞生物科技有限公司 | Amniotic membrane contact lens, preparation method and application |
| CN112415773A (en) * | 2020-12-03 | 2021-02-26 | 山东省眼科研究所 | Medicine-carrying contact lens for promoting corneal epithelium injury repair and preparation method thereof |
| CN112415773B (en) * | 2020-12-03 | 2022-10-04 | 山东省眼科研究所 | Medicine-carrying contact lens for promoting corneal epithelium injury repair and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101502458A (en) | Therapeutic corneal contact lens | |
| Trujillo-de Santiago et al. | Ocular adhesives: Design, chemistry, crosslinking mechanisms, and applications | |
| Tang et al. | Mussel-inspired injectable hydrogel and its counterpart for actuating proliferation and neuronal differentiation of retinal progenitor cells | |
| WO2017186168A1 (en) | Medical hydrogel composition, and medical hydrogel, preparation method therefor and application thereof | |
| Ruszczak et al. | Collagen as a carrier for on-site delivery of antibacterial drugs | |
| ES2318115T3 (en) | BIOACTIVE RETICULATED HYDROGEL MATRICES. | |
| JP4951621B2 (en) | Optical lens | |
| Shen et al. | Dual-crosslinked regenerative hydrogel for sutureless long-term repair of corneal defect | |
| JP6517443B2 (en) | Method of producing high functional suture coated with hyaluronate and high functional suture produced thereby | |
| US10611880B2 (en) | Oxime cross-linked biocompatible polymer hydrogels and methods of use thereof | |
| AU2006289625A1 (en) | Interpenetrating networks, and related methods and compositions | |
| CN105377963A (en) | Hydrophobic tissue adhesives | |
| US20230069580A1 (en) | Chemically cross-linked hydrogel and its microspheres, preparation method and application | |
| JPH02502261A (en) | Implantation of prosthetic devices | |
| US20230027018A1 (en) | Oxime Cross-Linked Biocompatible Polymer Hydrogels and Methods of Use Thereof | |
| TW201526922A (en) | Recipe for in-situ gel, and implant, drug delivery system formed thereby | |
| JP6518198B2 (en) | Compounds and compositions for drug release | |
| CN107519541B (en) | Hydrogel for preventing postoperative adhesion of abdominal cavity and preparation method and application thereof | |
| CN114159625B (en) | Composite hydrogel and preparation method and application thereof | |
| CN115322397B (en) | Zwitterionic hydrogel for preventing postoperative abdominal adhesion and preparation method thereof | |
| WO2024011448A1 (en) | High-adhesion artificial corneal endothelia graft, and preparation method therefor and use thereof | |
| WO2016049791A1 (en) | In-situ gel used as vitreous body substitute material, and preparation method and use thereof | |
| KR20180037938A (en) | Tissue anti-adhesion adjuvant and the prepartion method thereof | |
| CN112316219B (en) | Anti-adhesion hydrogel-silk scaffold composite membrane and preparation and application thereof | |
| Zheng et al. | Advances in biomaterials as a retinal patch for the repair of rhegmatogenous retinal detachment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090812 |